At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
GPX-150 for Injectiondrug
Likely dose
GPX-150 for Injection 265 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma
In Brief
A Phase 2 clinical trial evaluating GPX-150 for Injection for Soft Tissue Sarcoma. Completed, enrolled 22 participants across 4 sites.
Detailed Summary
This study will assess the safety and efficacy of GPX-150 administered intravenously every 3 weeks in the treatment of patients with soft tissue sarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Sarcoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartJan 2015
Primary CompletionNov 2015
Study CompletionAug 2016
TodayJul 2026
First PostedOct 17, 2014
Enrollment StartJan 7, 2015
Primary CompletionNov 11, 2015
Study CompletionAug 18, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.7 years ago
Interventions
GPX-150 for Injectiondrug
GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.